Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Sheaff Brock Investment Advisors LLC

Sheaff Brock Investment Advisors LLC lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 34.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,546 shares of the biopharmaceutical company’s stock after purchasing an additional 11,387 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $2,305,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. CIBC Asset Management Inc raised its holdings in Bristol-Myers Squibb by 9.2% in the third quarter. CIBC Asset Management Inc now owns 368,946 shares of the biopharmaceutical company’s stock valued at $19,089,000 after acquiring an additional 30,984 shares in the last quarter. Oak Harbor Wealth Partners LLC grew its position in shares of Bristol-Myers Squibb by 5.0% during the third quarter. Oak Harbor Wealth Partners LLC now owns 6,535 shares of the biopharmaceutical company’s stock worth $338,000 after acquiring an additional 312 shares during the last quarter. Neumann Capital Management LLC grew its position in shares of Bristol-Myers Squibb by 1.2% during the third quarter. Neumann Capital Management LLC now owns 20,623 shares of the biopharmaceutical company’s stock worth $1,067,000 after acquiring an additional 250 shares during the last quarter. Sargent Investment Group LLC bought a new position in shares of Bristol-Myers Squibb during the third quarter worth about $480,000. Finally, ING Groep NV grew its position in shares of Bristol-Myers Squibb by 540.6% during the third quarter. ING Groep NV now owns 1,034,653 shares of the biopharmaceutical company’s stock worth $53,533,000 after acquiring an additional 873,152 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Down 0.2 %

Shares of NYSE:BMY opened at $58.39 on Friday. The business’s 50 day moving average is $52.41 and its 200 day moving average is $47.07. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.08. The stock has a market cap of $118.43 billion, a price-to-earnings ratio of -16.29, a PEG ratio of 15.83 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same period in the prior year, the company earned $2.00 EPS. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.11%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -66.85%.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 1,830 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the purchase, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on BMY shares. BMO Capital Markets upped their price target on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research report on Tuesday. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Leerink Partnrs upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Jefferies Financial Group raised their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Finally, Citigroup raised their price target on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $54.07.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.